Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11201 - 11225 of 12702 in total
AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein). It is being developed by Acologix, Inc.
Investigational
Investigational
Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.
Investigational
AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.
Investigational
BF-37 for the treatment of atopic dermatitis and/or psoriasis. The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct the imbalances of the immune system that cause atopic dermatitis or psoriasis.
Investigational
Matched Description: … The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct …
TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.
Investigational
Matched Description: … TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in
GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase. A monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types...
Investigational
Matched Description: … older patients and is being studied in the treatment of other types of cancer. ... Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. ... antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in
HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection. HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.
Investigational
99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.
Investigational
G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. These viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores. MediGene uses these viruses, however, in a modified and "disarmed" form in order to...
Investigational
Matched Description: … as a therapeutic agent in humans. ... MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable …
99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo. Growth inhibition and prolonged survival of the myeloma tumor were obtained as evidences of anti tumor effect after treatment with 99mTc 14F7 Mab.
Investigational
Matched Description: … 99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo. …
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma...
Investigational
Matched Description: … Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, ... but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer …
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.
Investigational
NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in patients with Parkinson’s disease. NLX-P101 is being evaluated as...
Investigational
Matched Description: … glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in ... therapeutic drug when injected into this deep brain structure that is known to function abnormally in ... brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in
PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.
Investigational
ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.
Investigational
Matched Description: … ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models …
Investigational
AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.
Investigational
Investigational
Investigational
Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis . The drug made it to phase III trials before abandoned due to increased stroke.
Investigational
An aldotriose which is an important intermediate in glycolysis and in tryptophan biosynthesis.
Experimental
Matched Description: … An aldotriose which is an important intermediate in glycolysis and in tryptophan biosynthesis. …
Zinlirvimab is under investigation in clinical trial NCT03707977 (Dual Bnab Treatment in Children).
Investigational
Matched Description: … Zinlirvimab is under investigation in clinical trial NCT03707977 (Dual Bnab Treatment in Children). …
Displaying drugs 11201 - 11225 of 12702 in total